View Item 

Show simple item record

Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Program

dc.contributor.authorLangford, Aisha T.en_US
dc.contributor.authorResnicow, Kenen_US
dc.contributor.authorDimond, Eileen P.en_US
dc.contributor.authorDenicoff, Andrea M.en_US
dc.contributor.authorGermain, Diane St.en_US
dc.contributor.authorMccaskill‐stevens, Wortaen_US
dc.contributor.authorEnos, Rebecca A.en_US
dc.contributor.authorCarrigan, Angelaen_US
dc.contributor.authorWilkinson, Kathyen_US
dc.contributor.authorGo, Ronald S.en_US
dc.date.accessioned2014-05-21T18:02:51Z
dc.date.available2015-06-01T15:48:44Zen_US
dc.date.issued2014-03-15en_US
dc.identifier.citationLangford, Aisha T.; Resnicow, Ken; Dimond, Eileen P.; Denicoff, Andrea M.; Germain, Diane St.; Mccaskill‐stevens, Worta ; Enos, Rebecca A.; Carrigan, Angela; Wilkinson, Kathy; Go, Ronald S. (2014). "Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Program." Cancer 120(6): 877-884.en_US
dc.identifier.issn0008-543Xen_US
dc.identifier.issn1097-0142en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/106705
dc.publisherNational Academy of Sciencesen_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherMedical Researchen_US
dc.subject.otherCanceren_US
dc.subject.otherRacial/Ethnicen_US
dc.subject.otherAfrican Americansen_US
dc.subject.otherHispanicen_US
dc.subject.otherMinoritiesen_US
dc.subject.otherClinical Trialsen_US
dc.titleRacial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Programen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/106705/1/cncr28483.pdf
dc.identifier.doi10.1002/cncr.28483en_US
dc.identifier.sourceCanceren_US
dc.identifier.citedreferenceAdams‐Campbell LL, Ahaghotu C, Gaskins M, et al. Enrollment of African Americans onto clinical treatment trials: study design barriers. J Clin Oncol. 2004; 22: 730 ‐ 734.en_US
dc.identifier.citedreferenceAmerican Cancer Society. Economic Impact of Cancer. http://www.cancer.org/cancer/cancerbasics/economic‐impact‐of‐cancer. Accessed April 15, 2013.en_US
dc.identifier.citedreferenceNational Cancer Institute. SEER Stat Fact Sheets: All Sites. 2012; http://seer.cancer.gov/statfacts/html/all.html. Accessed April 9, 2013.en_US
dc.identifier.citedreferenceInstitute of Medicine. A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. National Academy of Sciences: Washington, DC; 2010.en_US
dc.identifier.citedreferenceMurthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race‐, sex‐, and age‐based disparities. JAMA. 2004; 291: 2720 ‐ 2726.en_US
dc.identifier.citedreferenceNational Cancer Institute. Fact Sheet: Cancer Health Disparities. 2012; http://www.cancer.gov/cancertopics/factsheet/disparities/cancer‐health‐disparities. Accessed May 10, 2013.en_US
dc.identifier.citedreferenceFord JG, Howerton MW, Lai GY, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer. 2008; 112: 228 ‐ 242.en_US
dc.identifier.citedreferenceWendler D, Kington R, Madans J, et al. Are racial and ethnic minorities less willing to participate in health research? PLoS Med. 2006; 3 ( 2 ): e19.en_US
dc.identifier.citedreferenceDurant RW, Legedza AT, Marcantonio ER, Freeman MB, Landon BE. Willingness to participate in clinical trials among African Americans and whites previously exposed to clinical research. J Cult Divers. 2011; 18: 8 ‐ 19.en_US
dc.identifier.citedreferenceMcCaskill‐Stevens W, McKinney MM, Whitman CG, Minasian LM. Increasing minority participation in cancer clinical trials: the minority‐based community clinical oncology program experience. J Clin Oncol. 2005; 23: 5247 ‐ 5254.en_US
dc.identifier.citedreferenceNational Cancer Institute. NCI Community Cancer Centers Program. Progress Reports and Tools/Community Hospitals. 2013; http://ncccp.cancer.gov/about/reports‐and‐tools.htm. Accessed April 10, 2013.en_US
dc.identifier.citedreferenceGrubbs SS, Go RS, Berger MZ, et al. Early success in narrowing age, gender, and racial disparities in clinical trial accrual: Targeted screening efforts through the National Cancer Institute Community Cancer Centers Program (NCCCP). J Clin Oncol. 2010; 29: ( 15 suppl ): 6110.en_US
dc.identifier.citedreferenceGonzalez M, Berger M, Brown T, et al. Using an Online Tool to Understand and Improve Clinical Trial Accruals. Oncol Issues. 2011; 26 ( 2 ): 50.en_US
dc.identifier.citedreferenceSt. Germain D, Denicoff AM, Dimond EP, et al. Use of the National Cancer Institute Community Cancer Centers Program (NCCCP) screening and accrual log to address cancer clinical trial accrual. J Oncol Pract. 2013 (accepted).en_US
dc.identifier.citedreferenceOffice of Management and Budget. Standards for the Classification of Federal Data on Race and Ethnicity. 2013; http://www.whitehouse.gov/omb/fedreg_race‐ethnicity. Accessed April 15, 2013.en_US
dc.identifier.citedreferenceBrown H, Prescott R. Applied Mixed Models in Medicine. New York, NY: John Wiley & Sons; 1999.en_US
dc.identifier.citedreferenceMicro Power & Light Co. Readability Formulas. 2013; http://www.micropowerandlight.com/rd.html. Accessed April 10, 2013.en_US
dc.identifier.citedreferenceTammemagi CM, Nerenz D, Neslund‐Dudas C, Feldkamp C, Nathanson D. Comorbidity and survival disparities among black and white patients with breast cancer. JAMA. 2005; 294: 1765 ‐ 1772.en_US
dc.identifier.citedreferenceAlbrecht TL, Eggly SS, Gleason ME, et al. Influence of clinical communication on patients' decision making on participation in clinical trials. J Clin Oncol. 2008; 26: 2666 ‐ 2673.en_US
dc.identifier.citedreferenceSchroen AT, Petroni GR, Wang H, et al. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials. 2010; 7: 312 ‐ 321.en_US
dc.identifier.citedreferenceAapro MS, Kohne CH, Cohen HJ, Extermann M. Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist. 2005; 10: 198 ‐ 204.en_US
dc.identifier.citedreferenceBaquet CR, Ellison GL, Mishra SI. Analysis of Maryland Cancer Patient Participation in National Cancer Institute‐Supported Cancer Treatment Clinical Trials. J Health Care Poor Underserved. 2009; 20 ( 2 suppl ): 120 ‐ 134.en_US
dc.identifier.citedreferenceHurria A, Cirrincione CT, Muss HB, et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol. 2011; 29: 1290 ‐ 1296.en_US
dc.identifier.citedreferenceCoyne CA, Xu R, Raich P, et al. Randomized, controlled trial of an easy‐to‐read informed consent statement for clinical trial participation: a study of the Eastern Cooperative Oncology Group. J Clin Oncol. 2003; 21: 836 ‐ 842.en_US
dc.identifier.citedreferenceCheung WY, Pond GR, Heslegrave RJ, Enright K, Potanina L, Siu LL. The contents and readability of informed consent forms for oncology clinical trials. Am J Clin Oncol. 2010; 33: 387 ‐ 392.en_US
dc.identifier.citedreferenceNational Cancer Institute. Simplification of Informed Consent Documents. 2013; http://www.cancer.gov/clinicaltrials/conducting/simplification‐of‐informed‐consent‐docs. Accessed July 17, 2013.en_US
dc.identifier.citedreferenceUS Census Bureau. 2010 Census Briefs. Overview of Race and Hispanic Origin: 2010. http://www.census.gov/prod/cen2010/briefs/c2010br‐02.pdf. Accessed July 16, 2013.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr28483.pdf
Size:
114.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.